1. Intravenous injection of cyclosporin A loaded lipid nanocapsules fights inflammation and immune system activation in a mouse model of diabetic retinopathy.
- Author
-
Bohley M, Dillinger AE, Braunger BM, Tamm ER, and Goepferich A
- Subjects
- Animals, Humans, Cyclosporine therapeutic use, Injections, Intravenous, Inflammation drug therapy, Disease Models, Animal, Cytokines, Immune System metabolism, Immune System pathology, Lipids, Diabetic Retinopathy drug therapy, Nanocapsules therapeutic use, Diabetes Mellitus drug therapy
- Abstract
Inflammation and immune system activation are key pathologic events in the onset and escalation of diabetic retinopathy (DR). Both are driven by cytokines and complement originating from the retinal pigment epithelium (RPE). Despite the RPE's pivotal role, there is no therapeutic tool to specifically interfere with the RPE-related pathomechanism. A therapy that addresses RPE cells and counteracts inflammation and immune response would be of paramount value for the early treatment of DR, where currently are no specific therapies available. Here, we utilized lipoprotein-mimetic lipid nanocapsules to deliver the anti-inflammatory and immunosuppressive drug cyclosporin A (CsA) to RPE cells. Using a mouse model of DR that mirrors all pathologic aspects of human DR, we demonstrate that intravenously applied CsA-loaded lipid nanocapsules comprehensively counteract inflammation and immune system activation. One single injection suppressed the expression of pro-inflammatory cytokines, dampened macrophage infiltration, and prevented macrophage and microglia activation in eyes with DR. This work shows that CsA-loaded lipid nanocapsules can offer new avenues for the treatment of DR., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF